Basket cover image
15 handpicked stocks

Venezuelan Oil's Return to U.S. Refiners

Chevron has resumed shipping crude oil from Venezuela to the U.S., marking a significant policy shift and restoring a key supply chain. This creates a potential investment opportunity in U.S. refiners and energy logistics companies that are set to benefit from the influx of desirable heavy crude.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at août 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

CVX

Chevron Corporation

CVX

Current price

$152.00

XOM

Exxon Mobil Corp.

XOM

Current price

$107.42

VLO

Valero Energy Corp.

VLO

Current price

$137.93

About This Group of Stocks

1

Our Expert Thinking

The resumption of Venezuelan crude oil shipments to the U.S. represents a significant geopolitical shift that could reconfigure regional energy flows. This development reopens access to heavy crude oil that American refineries, particularly those on the Gulf Coast, are specifically designed to process efficiently.

2

What You Need to Know

This group focuses on U.S. refiners and energy logistics companies positioned to benefit from renewed Venezuelan crude imports. These companies have the infrastructure optimised for heavy crude processing and transportation, potentially leading to improved operational efficiency and wider profit margins.

3

Why These Stocks

These stocks were handpicked by professional analysts based on their strategic positioning to capitalise on this specific policy change. The selection includes refiners with Gulf Coast facilities and midstream logistics companies essential for transporting and storing the incoming Venezuelan crude supply.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+4.82%

Group Performance Snapshot

4.82%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 4.82% over the next year.

9 of 15

Stocks Rated Buy by Analysts

9 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🛢️

Historic Supply Chain Reopens

For the first time in years, Venezuelan heavy crude is flowing back to U.S. refineries. This reopening of a key supply channel could significantly impact refining margins and operational efficiency for companies equipped to handle this specific type of oil.

💰

Cost-Effective Crude Advantage

Venezuelan crude offers refiners access to cost-effective heavy oil that's perfectly suited to Gulf Coast processing facilities. This could translate directly into improved profit margins for companies positioned to capitalise on this renewed trade relationship.

🎯

Strategic Policy Shift Impact

This represents a tactical investment opportunity based on a specific geopolitical development. Energy companies involved in refining and logistics are uniquely positioned to benefit from this significant shift in U.S. sanctions policy.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.